ORIC Pharmaceuticals, Inc.
240 E. Grand Avenue, 2nd Floor
South San Francisco
113 articles about ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals announced that Jacob Chacko, MD, Chief Executive Officer, will host one-on-one investor meetings on Wednesday, February 27 at the 8th Annual SVB Leerink Global Healthcare Conference, held Wednesday, February 27 through Friday, March 1, 2019 at the Lotte New York Palace in New York City.
ORIC Pharmaceuticals announced that Jacob Chacko, MD, Chief Executive Officer, will be presenting at the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019, at 7:30 a.m. PST. The conference will be held at the Westin St. Francis in San Francisco.
Mr. Panuwat will serve on the executive leadership team and will lead business and corporate development for ORIC.
ORIC Pharmaceuticals announced today that it will present at two upcoming investor conferences.
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Chief Executive Officer Jacob Chacko will host one-on-one investor meetings.
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.
Dr. Multani will oversee the clinical development of ORIC's lead compound, ORIC-101
2/21/2018A new chief executive officer and a fresh infusion of $50 million in Series C funding has given Bay Area ORIC Pharmaceuticals a shot in the arm as it continues to push development of its lead asset for treatment-resistant cancers.
ORIC Pharmaceuticals Announces $50 Million Series C Financing to Support Novel Therapies for Treatment-Resistant Cancers
Proceeds from the investment will be used to support clinical studies of ORIC-101, a potent small molecule inhibitor of the glucocorticoid receptor (GR) and the subject of an ongoing Phase 1 study.
Dr. Rich Heyman has over 25 years of biopharma experience and previously served as CEO of Seragon.
ORIC Pharma Announces First Subject Dosed in Phase I Clinical Study of Novel GR Antagonist with Planned Development for Oncology
ORIC Pharma announced today that the first subject in a Phase Ia clinical study has been dosed with ORIC-101, a potent small molecule inhibitor of the glucocorticoid receptor.
With Deep Scientific and Executive Bench and $53 Million in Series B Funds, ORIC Pharma Ready to Hit A Home Run